Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Priyadarshini Ravichandran"'
Autor:
Shih-Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, Morgan King-Richards, Yu-Ju Chen, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Sheila Waters, Jeffery L. Kutok, Marisa Peluso, Sujata Sharma, David T. Weaver, Jonathan A. Pachter, Kanti R. Rai, Nicholas Chiorazzi
Publikováno v:
Clinical Cancer Research. 29:1984-1995
Purpose: Inhibitors of Bruton's tyrosine kinase (BTKi) and PI3K (PI3Ki) have significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet therapeutic need. Hence, we sought
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e1d04de0e092c271491cfd78719407a
https://doi.org/10.1158/1078-0432.ccr-22-2386
https://doi.org/10.1158/1078-0432.ccr-22-2386
Autor:
Nicholas Chiorazzi, Kanti R. Rai, Jonathan A. Pachter, David T. Weaver, Sujata Sharma, Marisa Peluso, Jeffery L. Kutok, Sheila Waters, Yasmine Kieso, Michael Ibrahim, Priyadarshini Ravichandran, Yu-Ju Chen, Morgan King-Richards, Gerardo Ferrer, Jacqueline C. Barrientos, Shih-Shih Chen
Effects of inhibition of PI3K isoforms on CLL-cell proliferation, survival, and migration.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b915f53399d7fc62583f04718343a06
https://doi.org/10.1158/1078-0432.22820110.v1
https://doi.org/10.1158/1078-0432.22820110.v1
Autor:
Nicholas Chiorazzi, Kanti R. Rai, Jonathan A. Pachter, David T. Weaver, Sujata Sharma, Marisa Peluso, Jeffery L. Kutok, Sheila Waters, Yasmine Kieso, Michael Ibrahim, Priyadarshini Ravichandran, Yu-Ju Chen, Morgan King-Richards, Gerardo Ferrer, Jacqueline C. Barrientos, Shih-Shih Chen
Purpose:Inhibitors of Bruton's tyrosine kinase (BTKi) and PI3K (PI3Ki) have significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet therapeutic need. Hence, we sought
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c3d6e09a3e1db0191cbb96707dd981d
https://doi.org/10.1158/1078-0432.c.6605170
https://doi.org/10.1158/1078-0432.c.6605170
Autor:
Nicholas Chiorazzi, Kanti R. Rai, Jonathan A. Pachter, David T. Weaver, Sujata Sharma, Marisa Peluso, Jeffery L. Kutok, Sheila Waters, Yasmine Kieso, Michael Ibrahim, Priyadarshini Ravichandran, Yu-Ju Chen, Morgan King-Richards, Gerardo Ferrer, Jacqueline C. Barrientos, Shih-Shih Chen
IC50 values of PI3K isoform inhibitors used. Duvelisib5, IPI-3063 (PI3K-d inhibitor)5, IPI-549 (PI3K-g inhibitor used in vitro)50, IPI-5243 (PI3K-g inhibitor used in vivo).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ead5388474787e49d884681dd3bc434
https://doi.org/10.1158/1078-0432.22652506
https://doi.org/10.1158/1078-0432.22652506
Autor:
Shih-Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Jeffery L. Kutok, Marisa Peluso, Sujata Sharma, David T. Weaver, Jonathan A. Pachter, Kanti R. Rai, Nicholas Chiorazzi
Publikováno v:
Cancer Research. 83:4933-4933
Duvelisib (IPI-145), a first-in-class, oral, dual PI3K-δ,γ inhibitor, has been approved by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic and follicular lymphoma. Duvelisib potently inhibits PI3K-δ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beeeae09c6ee024593abe7f007f8fe86
https://doi.org/10.1158/1538-7445.am2023-4933
https://doi.org/10.1158/1538-7445.am2023-4933
Autor:
Daniel S Ginsburg, Priyadarshini Ravichandran, Azad L Gucwa, Himali Vashishtha, Simon A Davis
Publikováno v:
DNA and Cell Biology. 39:2077-2084
The Tip60 lysine acetyltransferase is a tumor suppressor in most cancers but an oncogene in prostate and gastric cancer. Tip60 is commonly found in the nucleus, where it acetylates proteins involved in transcription, DNA repair, and chromatin; howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e53dc675f201f9ec9abdc7f923ff9fe
https://doi.org/10.1089/dna.2020.5980
https://doi.org/10.1089/dna.2020.5980
Autor:
Shih-Shih Chen, Jacqueline Barrientos, Gerardo Ferrer, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Jeff Kutok, Marisa Peluso, Sujata Sharma, David Weaver, Jonathan Pachter, Kanti Rai, Nicholas Chiorazzi
Inhibitors of Bruton’s Tyrosine Kinase (BTKi) and phosphoinositide 3-kinase (PI3Ki) have significantly improved therapy of chronic lymphocytic leukemia (CLL). However, the emergence of resistance to BTKi has introduced an unmet therapeutic need. He
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1385a20f07af2ea0025892daa852548
https://doi.org/10.21203/rs.3.rs-701669/v1
https://doi.org/10.21203/rs.3.rs-701669/v1
Autor:
Constantine S. Tam, He Zhou, Alan G. Ramsay, Jacqueline C. Barrientos, Priyadarshini Ravichandran, Gerardo Ferrer, Nicholas Chiorazzi, Shih-Shih Chen, Michael Ibrahim, Kanti R. Rai, Steven L. Allen, Jonathan E. Kolitz, Natalia C. Couto-Francisco
Publikováno v:
Blood. 134:477-477
Bruton's tyrosine kinases inhibitors (BTKis) represent major advances in CLL therapy. However resistance to this form of therapy is emerging, and such patients often progress more rapidly. Hence there is an important need for therapies that address r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0ca537db719bff41becde9babeeaf29
https://doi.org/10.1182/blood-2019-127255
https://doi.org/10.1182/blood-2019-127255
Autor:
Anish Sathianathan, Daniel S. Ginsburg, Leah S. Cohen, Priyadarshini Ravichandran, Angelo Messina, Marci J. Swede, Sherwin Shaju, Jake M. Lippi
Publikováno v:
The Journal of biological chemistry. 291(40)
NuA4 is the only essential lysine acetyltransferase complex in Saccharomyces cerevisiae, where it has been shown to stimulate transcription initiation and elongation. Interaction with nucleosomes is stimulated by histone H3 Lys-4 and Lys-36 methylati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a492f361fa3731d0f8a37242ce50e60e
https://pubmed.ncbi.nlm.nih.gov/27535225
https://pubmed.ncbi.nlm.nih.gov/27535225
Autor:
Thomas M. Herndon, Nicholas Chiorazzi, Shih-Shih Chen, Priyadarshini Ravichandran, Adrian Wiestner, Michael Ibrahim, Xiao J. Yan, Barbara Sherry, Kanti R. Rai, Clare Sun
Publikováno v:
Blood. 132:1836-1836
Chronic lymphocytic leukemia (CLL) cells actively participate in the formation of the tumor microenvironment (TME). The interplay of CLL cells and leukemia-supporting cells such as Th2 cells and regulatory T cells (Tregs) promotes a leukemia-supporti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::458da0536491f54d78092c4913afac5c
https://doi.org/10.1182/blood-2018-99-119843
https://doi.org/10.1182/blood-2018-99-119843